Standardization of the expression of 12-LOX in platelet-rich plasma to the concentration of TGB and the number of PLT significantly increases the sensitivity of the test and could be used as biomarker for the assessment of risk for the prostate cancer. The gene discussed is ALOX12; the disease is Familial prostate cancer.